[{"data":1,"prerenderedAt":34},["ShallowReactive",2],{"$feu2t73nMphCum6FqMT03B4MRsh4ALVJBL0AtIitS40g":3},{"code":4,"show":5,"msg":6,"data":7,"status":33},1,0,"",{"info":8,"next":20,"prev":25,"others":30},{"cate_name":9,"id":10,"cid":11,"title":12,"desc":13,"title_cn":14,"desc_cn":15,"content_cn":16,"image":17,"content":18,"is_show":4,"home_recommend":4,"publish_at":19},"好物",4,3,"SciBrunch Therapeutics Completes Over $35 Million Pre-A Round Financing, Totaling $65 Million in Two Recent Rounds","SciBrunch Therapeutics announced the completion of an oversubscribed Pre-A round financing of over $35 million.","思璞锐SciBrunch完成超3500万美元Pre-A轮融资，近期两轮融资合计6500万美元","思璞锐SciBrunch（上海思璞锐医药科技有限公司，SciBrunch Therapeutics Inc.）宣布完成超额认购的Pre-A轮融资，金额超3500万美元。本轮融资由生物医药领域知名投资机构弘晖基金(HLC)领投，InnoPinnacle Fund跟投，老股东汉康资本、博远资本、LongRiver江远投资和骊宸投资持续加码。","\u003Cp style=\"text-align: start;\">思璞锐SciBrunch（上海思璞锐医药科技有限公司，SciBrunch Therapeutics Inc.）宣布完成超额认购的Pre-A轮融资，金额超3500万美元。本轮融资由生物医药领域知名投资机构弘晖基金(HLC)领投，InnoPinnacle Fund跟投，老股东汉康资本、博远资本、LongRiver江远投资和骊宸投资持续加码。这是继2025年6月获得天使轮融资后，思璞锐SciBrunch在一年内完成的又一轮融资，两轮融资合计6500万美元。\u003C/p>\u003Cp style=\"text-align: start;\">\u003Cbr>\u003C/p>\u003Cp style=\"text-align: start;\">\u003Cbr>\u003C/p>\u003Cp style=\"text-align: center;\">\u003Cimg src=\"https://api-scibrunch.hellokoma.com/uploads/images/20260430/202604301151480779b0348.png\" alt=\"\" data-href=\"\" style=\"width: 404.38px;height: 120.47px;\">\u003C/p>\u003Cp style=\"text-align: center;\">\u003Cbr>\u003C/p>\u003Cp style=\"text-align: start;\">\u003Cbr>\u003C/p>\u003Cp style=\"text-align: start;\">\u003Cimg src=\"https://api-scibrunch.hellokoma.com/uploads/images/20260430/2026043013052050f606794.png\" alt=\"\" data-href=\"\" style=\"\">\u003C/p>\u003Ch5 style=\"text-align: start;\">\u003C/h5>\u003Ch5 style=\"text-align: start;\">\u003Cspan style=\"font-size: 19px;\">\u003Cstrong>本轮融资将主要用于：\u003C/strong>\u003C/span>\u003C/h5>\u003Cul>\u003Cli style=\"text-align: start;\">加速核心管线SPR1020的临床开发，作为下一代高选择性Parp1抑制剂，其透脑特性显著，已于2026年1月8日完成首例患者给药；\u003C/li>\u003Cli style=\"text-align: start;\">推进新一代创新分子胶型RAS抑制剂的IND开发工作，探索RAS突变难治性肿瘤（结直肠癌、胰腺癌、非小细胞肺癌等）的临床潜力，全方位赋能打造RAS驱动型癌症的治疗优选。\u003C/li>\u003C/ul>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cimg src=\"https://api-scibrunch.hellokoma.com/uploads/images/20260430/202604301307267a5752179.png\" alt=\"\" data-href=\"\" style=\"\"/>\u003C/p>\u003Ch5 style=\"text-align: start;\">\u003C/h5>\u003Ch5 style=\"text-align: start;\">\u003Cspan style=\"font-size: 19px;\">\u003Cstrong>思璞锐SciBrunch创始人、董事长兼CEO胡滔博士表示：\u003C/strong>\u003C/span>\u003C/h5>\u003Cp>衷心感谢各位投资人的大力支持与信任，本轮融资是对思璞锐阶段性成果的持续肯定。我们始终保持着对行业的敏锐度和饥渴感，力图在管线的创新性、质量和速度方面展现出强大的执行效率和竞争优势，专注于在肿瘤创新药领域取得突破。\u003C/p>\u003Ch5 style=\"text-align: start;\">\u003C/h5>\u003Cp>\u003Cbr>\u003C/p>\u003Ch5 style=\"text-align: start;\">\u003Cspan style=\"font-size: 19px;\">\u003Cstrong>弘晖基金(HLC)表示：\u003C/strong>\u003C/span>\u003C/h5>\u003Cp>很高兴看到思璞锐这一年所取得的成绩。思璞锐团队在小分子设计开发以及BD合作方面颇有经验，目前管线丰富，皆有Best-in-Class潜质。我们期待与思璞锐一同推进尖端药物的研发管线，更好造福患者。\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch3 style=\"text-align: start;\">\u003Cspan style=\"font-size: 19px;\">\u003Cstrong>关于弘晖基金(HLC)\u003C/strong>\u003C/span>\u003C/h3>\u003Cp>基于在化学、生物学和材料工程学等核心领域的深刻认知，立足独立深度研究和体系化赋能服务，弘晖基金矢志通过对实体经济和科技创新的长期价值投资为生产效率的变革和人民健康生活的提升创造持续积极影响。至今，弘晖基金已投资超150 家优质企业，33 家企业完成上市，50 余家企业完成并购及转让退出，包括：迈瑞医疗、联影医疗、康龙化成、泰格医药、 鱼跃医疗、 威高血净、维亚生物、中慧生物、劲方医药、普米斯、归创医疗、兆维科技、长江存储、思摩尔、亚电科技、拓烯科技、弈柯莱、众擎机器人、千寻智能、首形科技等。\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch3 style=\"text-align: start;\">\u003Cspan style=\"font-size: 19px;\">\u003Cstrong>关于InnoPinnacle Fund\u003C/strong>\u003C/span>\u003C/h3>\u003Cp>InnoPinnacle Fund是由信达生物主导发起设立的美元创投基金。基金独立运营，专注于投资全球创新药、生物技术及产业链相关领域的领先企业，着重赋能下一代生物医药和突破性技术，以解决未被满足的临床需求，并发挥产业力量和特色优势，与优秀的创业者携手同行，构建合作共赢的创新生态圈。\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Ch3 style=\"text-align: start;\">\u003Cspan style=\"font-size: 19px;\">\u003Cstrong>关于思璞锐SciBrunch\u003C/strong>\u003C/span>\u003C/h3>\u003Cp style=\"text-align: start;\">思璞锐SciBrunch是一家处于临床阶段的研发型生物技术公司，专注于小分子抗肿瘤药物迭代创新。公司由资深连续创业者胡滔博士携手药物化学专家张杨博士共同创立，以新视角挖掘临床验证靶点的开发潜力，前瞻性地进行差异化的产品性能设计，秉承“做对、做深、做极致”的理念，打造具有全球竞争力的产品。\u003C/p>","https://api-scibrunch.hellokoma.com/uploads/images/20260416/20260416153543a1ff13477.jpg","\u003Cp>\u003Cspan style=\"font-family: Arial;\">SciBrunch Therapeutics announced the completion of an oversubscribed Pre-A round financing of over $35 million.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">This round was led by H\u003C/span>ighLight Capital\u003Cspan style=\"font-family: Arial;\">, a prominent investor in the biopharmaceutical sector, with participation from InnoPinnacle Fund. Existing shareholders including \u003C/span>\u003Cspan style=\"color: rgb(30, 41, 59);\">Hankang\u003C/span>\u003Cspan style=\"font-family: Arial;\"> Capital, B\u003C/span>ioTrack\u003Cspan style=\"font-family: Arial;\"> Capital, LongRiver Investment\u003C/span>s\u003Cspan style=\"font-family: Arial;\">, and \u003C/span>Elikon Venture\u003Cspan style=\"font-family: Arial;\"> also increased their investment.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">This marks another financing round completed by SciBrunch within one year following its angel round in June 2025, bringing the total capital raised in the two rounds to $65 million.\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cp>\u003Cspan style=\"font-family: Arial;\">The proceeds of this financing round will be mainly used for:\u003C/span>\u003C/p>\u003Cp>\u003Cbr>\u003C/p>\u003Cul>\u003Cli>\u003Cspan style=\"font-family: Arial;\">Accelerating the clinical development of its core pipeline candidate SPR1020, a next-generation highly selective PARP1 inhibitor with significant brain penetration potential. The first patient was dosed on January 8, 2026.\u003C/span>\u003C/li>\u003C/ul>\u003Cp>\u003Cbr>\u003C/p>\u003Cul>\u003Cli>\u003Cspan style=\"font-family: Arial;\">Advancing IND-enabling studies for a new generation of innovative molecular glue RAS inhibitors, exploring their clinical potential in RAS-mutated refractory tumors including colorectal cancer, pancreatic cancer, and non-small cell lung cancer, with the goal of developing preferred therapies for RAS-driven cancers.\u003C/span>\u003C/li>\u003C/ul>\u003Cp style=\"text-align: left;\">\u003Cbr>\u003C/p>",1769702400,{"publish_time":21,"id":4,"title":22,"title_cn":23,"publish_at":24},"2025-06-05","SciBrunch Therapeutics Completes Over RMB 200 Million Angel Round Financing, Focused on Innovative Small-Molecule Oncology Drugs","思璞锐完成超2亿元天使轮融资，专注小分子抗肿瘤创新药开发",1749101112,{"publish_time":26,"id":11,"title":27,"title_cn":28,"publish_at":29},"2026-01-09","First Patient In! SciBrunch Initiates Phase I Clinical Trial of Highly Selective PARP1 Inhibitor SPR1020","首例患者入组！思璞锐启动高选择性PARP1抑制剂SPR1020临床I期试验",1767936313,[31,32],{"publish_time":26,"id":11,"title":27,"title_cn":28,"publish_at":29},{"publish_time":21,"id":4,"title":22,"title_cn":23,"publish_at":24},200,1778239543633]